Filtered By:
Cancer: Colorectal Cancer

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 198 results found since Jan 2013.

Risk factors for early-onset colorectal cancer: a population-based case –control study in Ontario, Canada
ConclusionModifiable factors, particularly sedentary behavior and unhealthy diet including sugary drink consumption, may be associated with EO-CRC risk. Our findings, if replicated, may help inform prevention strategies targeted at younger persons.
Source: Cancer Causes and Control - June 13, 2021 Category: Cancer & Oncology Source Type: research

PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an * In the Dragonfly: *NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Late Breaking Abstract - DCLK1 mediates thrombin-induced IL-8/CXCL8 expression in lung epithelial cells
Airway neutrophilia has been known correlated with asthma severity. Thrombin plays a crucial role in asthma. Thrombin can induce IL-8/CXCL8 expression, a potent chemoattractant for neutrophils, in lung epithelial cells. Doublecortin-like kinase 1 (DCLK1) is a protein kinase that has been identified as a tumor stem cell marker in colon and pancreatic cancer. Here we investigated the role of DCLK1 in thrombin-induced IL-8/CXCL8 expression in human lung epithelial cells. Thrombin-induced IL-8/CXCL8 release was attenuated by DCLK1 siRNA or LRKK2-IN-1 (DCLK1 inhibitor) in BEAS-2B and A549 cells. Moreover, thrombin-induced IL-8/...
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Yuliani, F. S., Chen, J.-Y., Cheng, W.-H., Wen, H.-C., Chen, B.-C., Lin, C.-H. Tags: Allergy and immunology Source Type: research

What Are Common Gastrointestinal Polyposes in Children?
Discussion Bloody stools or blood in the diaper is a relatively common complaint in general pediatrics. For most patients it is often a minor concern. Commonly it is a transient problem (e.g. rectal fissure caused by constipation or trauma) or often not blood (e.g. urate crystals in the diaper, food, menses, etc.). Real blood does occur with an identifiable cause such as long distance running or heavy exercise, or milk protein allergy/sensitivity that improves with a milk-restricted diet. Many more serious causes are associated with heavier or more recalcitrant bleeding, increased defecation, abdominal pain, poor eating an...
Source: PediatricEducation.org - January 24, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

Changes in peripheral blood eosinophils may predict colorectal cancer - A retrospective study
CONCLUSION: We found higher risk for CRC in patients with a positive linear increase in peripheral eosinophils over time. This may be an indirect clue that eosinophils play a role in the pathogenesis of CRC. Linear changes in ANE may be used in the future to improve screening measures for CRC.TRIAL REGISTRATION: Not relevant.PMID:36254184 | PMC:PMC9531278 | DOI:10.1016/j.waojou.2022.100696
Source: Cancer Control - October 18, 2022 Category: Cancer & Oncology Authors: Yossi Rosman Tzipi Hornik-Lurie Keren Meir-Shafrir Idit Lachover-Roth Anat Cohen-Engler Ariel Munitz Ronit Confino-Cohen Source Type: research

In vitro and in vivo Evidence on Intra-tumor Injection of Allogeneic Serum for Immunotherapy in a Mouse Model of Colon Cancer
Iran J Allergy Asthma Immunol. 2022 Oct 26;21(5):549-560. doi: 10.18502/ijaai.v21i5.11042.ABSTRACTIt is believed that preformed antibodies are responsible for blood transfusion reactions and transplant rejections. In order to remove a tumor, the tissue must be rejected. On the basis of transfusion reaction and transplantation immunology, we hypothesized that allogeneic serum can inhibit tumor growth when injected intra-tumor. Initially, an in vitro cytotoxicity test was conducted using the C57BL/6 serum (intact or decomplemented) in combination with the BALB/c-originating CT26 cell line. The CT26 cell line was used to esta...
Source: Cancer Control - November 7, 2022 Category: Cancer & Oncology Authors: Erfan Basirat Danial Dehghan Ardeshir Abbasi Nafiseh Pakravan Source Type: research

Biallelic TLR4 deficiency in humans
J Allergy Clin Immunol. 2022 Nov 23:S0091-6749(22)01373-2. doi: 10.1016/j.jaci.2022.08.030. Online ahead of print.NO ABSTRACTPMID:36462956 | DOI:10.1016/j.jaci.2022.08.030
Source: Clinical Colorectal Cancer - December 3, 2022 Category: Cancer & Oncology Authors: Melania Capitani Ahmad A Al-Shaibi Sumeet Pandey Lisa Gartner Henry Taylor Satanay Z Hubrack Nourhen Agrebi Muneera Jassim Al-Mohannadi Saad Al Kaabi Thomas Vogl Johannes Roth Daniel Kotlarz Christoph Klein Adrian K Charles Vinayan Vijayakumar Mohammed Yo Source Type: research

Hypersensitivity reactions to folinic acid: mechanisms involved based on two case reports and a literature review
Allergy Asthma Clin Immunol. 2022 Dec 22;18(1):107. doi: 10.1186/s13223-022-00752-5.NO ABSTRACTPMID:36550565 | DOI:10.1186/s13223-022-00752-5
Source: Clinical Colorectal Cancer - December 22, 2022 Category: Cancer & Oncology Authors: Matve ï Apraxine Marc Van den Eynde Astrid De Cuyper Fran çoise Pirson Source Type: research

What Causes Bloating —and What to Do About It
Bloating is an uncomfortable feeling of fullness or pressure in the abdomen. Like an overinflated balloon, a bloated belly can feel packed with air, and in some cases may be visibly enlarged or distended. Bloating is a common issue. By some estimates, up to 30% of Americans experience it from time to time. In a majority of cases, the sensation is temporary and tolerable. It may not be pleasant, but on its own it’s usually not cause for serious concern. However, bloating can also be a symptom of an underlying gastrointestinal problem or disorder, including some issues that warrant a medical provider’s urgent att...
Source: TIME: Health - January 4, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Gut health healthscienceclimate Source Type: news